Bond.az White LogoBond.az Black Logo

Goldman Sachs Reinstates Ageas with Neutral

Goldman Sachs reinstates Ageas with Neutral rating, price target EUR70.

Sophia Anderson
BySophia Anderson- Senior Editor
|
0

Bond.az - Goldman Sachs reinstated coverage on Ageas (AGS:BB) (OTC:AGESY) with a Neutral rating and a price target of EUR70.00. The stock trades at a P/E ratio of 7.46.

Analyst Andrew Baker cited the company's complexity following recent mergers and acquisitions. Ageas now fully owns AG Insurance, Belgium's leading insurer, and is a top-three player in UK personal lines.

Goldman Sachs believes Ageas is entering an execution phase with limited upside risk. The company returned 26% over the past year and has a 4.65% dividend yield, paying dividends for 17 consecutive years.

More News
Yesterday / 21:33
|
306

Bernstein Starts Incyte with Growth Concerns

Bernstein starts Incyte coverage with Market Perform rating and $99 target, highlighting Jakafi patent loss and growth concerns.

0
Yesterday / 21:32
|
759

Bernstein Initiates BioNTech Coverage with Concerns

Bernstein initiates BioNTech coverage with Market Perform rating and $96 target, citing pipeline concerns.

0
Yesterday / 21:31
|
915

Bernstein Starts Revolution Med at Market Perform

Bernstein initiates Revolution Medicines coverage with Market Perform rating and $151 target. Stock trades at $153.73.

0
Yesterday / 21:30
|
792

Bernstein Initiates Neurocrine with Outperform Rating

Bernstein initiates Neurocrine Biosciences with an outperform rating and $221 price target. Highlights Crenessity's potential and stock upside.

0
Yesterday / 20:02
|
615

TD Cowen Cuts Orthofix Medical Target to $12

TD Cowen cuts Orthofix Medical price target to $12 on CMS rate cuts. Stock near 52-week low. Hold rating maintained.

0
Yesterday / 18:52
|
535

BofA Raises Nio Price Target to $6.80

BofA raises Nio price target to $6.80 on improved margin outlook. Get the latest analysis and stock insights at Bond.az.

0
Yesterday / 18:02
|
442

Chemours, Solstice Stock Drops: Buying Opportunity

BMO Capital Markets sees recent declines in Chemours and Solstice stocks as buying opportunities after EPA extends refrigerant transition deadline.

0
Yesterday / 17:51
|
885

BTIG cuts Lightspeed price target to $12

BTIG cut Lightspeed POS price target to $12 from $15, maintaining Buy. Stock at $8.38. Company guides 12-16% organic gross profit growth for FY2027.

0
Yesterday / 17:10
|
264

Truist Raises Keysight Price Target to $376 on Strong Orders

Truist Securities hikes Keysight price target to $376 after record quarterly orders with 48% growth. Stock up 111% in a year but premium valuation remains.

0
Yesterday / 14:42
|
387

Truist raises Nvidia target to $307

Truist Securities boosts Nvidia price target to $307 from $287, reiterates Buy rating amid strong AI demand and growth prospects.

0
Yesterday / 14:42
|
757

Truist Cuts Intuit Price Target

Truist Securities cuts Intuit price target to $410 from $500 but keeps Buy rating. TurboTax growth slows amid DIY filer weakness.

0
Yesterday / 14:41
|
271

Truist cuts Lowe's price target to $255

Truist Securities cuts Lowe's price target to $255 from $280, maintaining Buy rating. Expense timing pressure expected to weigh on Q2 earnings.

0
...
Goldman Sachs Reinstates Ageas with Neutral | Bond.az